TARGETING OBESITY: PHARMACOLOGICAL THERAPIES, BIOCHEMICAL AND PHYSIOLOGICAL MECHANISMS AND RENAL STONE RISK – CURRENT DRUGS AND FUTURE PERSPECTIVES
DOI:
https://doi.org/10.48047/2xfvhq46Keywords:
Obesity, Pharmacological therapies, Biochemical mechanismsAbstract
Obesity remains a leading public health concern worldwide, contributing to various comorbidities, including type 2 diabetes, cardiovascular diseases, and metabolic syndrome. This study aims to evaluate the effectiveness and underlying biochemical mechanisms of pharmacological therapies for obesity treatment. The study focuses on currently approved anti-obesity drugs and their impact on biochemical pathways such as appetite regulation, fat metabolism, and energy expenditure. A case control study was conducted with obese subjects assigned to either drug treatment or placebo groups. The results demonstrated a statistically significant reduction in body weight in the treatment group (p < 0.05), with notable improvements in metabolic parameters including blood glucose and lipid profile. Furthermore, biochemical markers of appetite regulation and fat oxidation were significantly altered, providing insight into the molecular mechanisms underlying the efficacy of these therapies. These findings highlight the therapeutic potential of current pharmacological interventions and point to new directions for future drug development, focusing on targeting specific molecular pathways involved in obesity. The study provides a comprehensive understanding of the biochemical basis of obesity treatment and underscores the need for further research to optimize therapeutic strategies.
Downloads
References
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S. (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E. (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393.
Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ. (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
Setmelanotide. (2023). In Wikipedia.
Yue, K., Haokun, Y., Rong, N., Xuxiang, Z., Hongtao, Z., & Xin, N. (2025). Progress of the anti-obesity of Berberine. arXiv.
Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ. (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S. (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E. (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393.
Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ. (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
Setmelanotide. (2023). In Wikipedia.
Yue, K., Haokun, Y., Rong, N., Xuxiang, Z., Hongtao, Z., & Xin, N. (2025). Progress of the anti-obesity of Berberine. arXiv.
Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ. (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S. (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E. (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393.
Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ. (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
Setmelanotide. (2023). In Wikipedia.
Yue, K., Haokun, Y., Rong, N., Xuxiang, Z., Hongtao, Z., & Xin, N. (2025). Progress of the anti-obesity of Berberine. arXiv.
Tiryakioğlu, P., Yılmaz, H., Demir, İ., & Yılmaz, İ. (2023). Current pharmacological approaches in obesity treatment. DAHUDER Medical Journal, 3(2), 32–48.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A. E., & Mantzoros, C. S. (2019). Pharmacotherapy of obesity: Available medications and drugs under investigation. Metabolism, 92, 170–192.
Montan, P. D., Sourlas, A., Olivero, J., Silverio, D., Guzman, E., & Kosmas, C. E. (2019). Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Annals of Translational Medicine, 7(16), 393
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Muhammad Nadeem Shafique, Muhammad Saeed, Nida Shafi, Jamil Ahmed Siddiqui , Javeria Sarfraz, Azhar Ijaz, Farah Naz Tahir (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
